A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
for Cerebral Adrenoleukodystrophy (cALD)
4 locations incl. Palo Alto
Sponsor: Minoryx Therapeutics, S.L.
Sex: Male·Age: 18+
Code: NCT05819866·Phase 3·Recruiting·Listed Apr 2023